MarketPeel
Insider Trading Intelligence
Pricing
…
RD

Robert Michael Dudley

RNAZ
CHIEF EXECUTIVE OFFICER · TRANSCODE THERAPEUTICS, INC. · CIK 0001854161
FILING MIX · LIFETIME100%/0%
BUYS
11
SELLS
0
TOTAL VALUE
$281.9K
COMPANIES
1
ACTIVE SINCE
Feb 2022
HOLDINGS NOW
180,262
AVG SELL PX
—
TRADE KIND
SHOWING 11 / 11
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Robert Michael Dudley, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+14.29%-6.39%-0.38%-6.01%-2.42%—
14d7+0.00%-14.47%-2.22%-12.25%-12.88%—
30d7+0.00%-19.88%-2.48%-17.40%-18.05%—
60d7+0.00%-39.31%+1.00%-40.31%-39.66%—
90d7+0.00%-58.82%+3.02%-61.85%-62.49%—
180d7+0.00%-85.14%+5.65%-90.79%-98.28%—
1y7+0.00%-95.19%+19.55%-114.74%-125.03%—
2y7+0.00%-99.95%+41.35%-141.31%-139.87%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RNAZ · 180,262 shares · as of Sep 28, 2023
0228,029456,057684,086912,1142023SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2022
2022
2023
2023
2023
FLOW · 11 buys / 0 sellsCOVERAGE · 7 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
98,000$0.51$50.0K180,262Sep 28, 2023Oct 2, 2023 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
12,000$2.65$31.8K82,262Jun 21, 2023Jun 22, 2023 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
6,607$2.55$16.8K70,262Jun 20, 2023Jun 22, 2023 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
19,000$2.76$52.4K61,155Jun 9, 2023Jun 14, 2023 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
19,000$2.76$52.4K912,114Jun 9, 2023Jun 13, 2023 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
735,000——735,000May 19, 2023May 19, 2023 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
135,000——135,000Dec 12, 2022Dec 14, 2022 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
20,000$1.15$23.0K893,114Sep 14, 2022Sep 16, 2022 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
2,000$1.87$3.7K873,114May 31, 2022Jun 1, 2022 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
28,000$1.84$51.6K871,114May 27, 2022Jun 1, 2022 ↗View →
RNAZ
TRANSCODE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
135,000——135,000Feb 1, 2022Feb 3, 2022 ↗View →
Other insiders · RNAZ
Loading peer insiders…
About this filer
CIK 0001854161
ROLE
Chief Executive Officer
PRIMARY
RNAZ
COMPANIES
1
ACTIVE SINCE
Feb 2022
MARKETPEEL · /INSIDER/0001854161DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback